-

11:16:23 AM

NVCN Stock News

NVCN - Neovasc Inc

07/28/22 9:00 AM

Nasdaq : NVCN

conferencesearningslow float

Neovasc to Report Second Quarter Financial Results on August 11, 2022

via NewMediaWire – Neovasc Inc. ( NASDAQ, TSX : NVCN), will report financial results for the quarter ended June 30, 2022 on Thursday, August 11, 2022. Neovasc’s President and Chief Executive Officer Fred Colen, and Chris Clark, Chief

RHEA-AI

neutral

07/26/22 9:05 AM

Nasdaq : NVCN

fda approvallow float

Neovasc Announces FDA Approval of Planned COSIRA II Sub-studies and Single Arm Registry to Allow Inclusion of Additional Specified Patient Populations

via NewMediaWire – Neovasc, Inc. ("Neovasc" or the "Company") ( NASDAQ, TSX : NVCN) today announced the United States Food and Drug Administration (“FDA”) has approved a protocol supplement to the COSIRA-II Investigational Device

RHEA-AI

positive

07/05/22 9:05 AM

Nasdaq : NVCN

low float

Neovasc Announces Direct Sales Operations in United Kingdom

via NewMediaWire – Neovasc, Inc. ("Neovasc" or the "Company") ( NASDAQ, TSX : NVCN) today announced that the company has expanded its direct sales

RHEA-AI

very positive

06/08/22 9:05 AM

Nasdaq : NVCN

conferenceslow float

Neovasc to Participate in Sidoti & Co. Summer Small Cap Virtual Investor Conference

Neovasc, Inc. (Neovasc or the Company) ( NASDAQ , TSX : NVCN) today announced that its management team will be participating in the 2022 Sidoti & Co. Summer Small Cap Virtual Investor Conference to be held June

RHEA-AI

neutral

05/23/22 4:05 PM

Nasdaq : NVCN

conferenceslow float

Neovasc to Participate in H.C. Wainwright Global Investment Conference

Neovasc, Inc. (Neovasc or the Company) ( NASDAQ , TSX : NVCN) today announced that its management team will be participating in the H.C. Wainwright Global Investment Conference to be held May 23-26, 2022. Fred Colen,

RHEA-AI

neutral

05/16/22 9:05 AM

Nasdaq : NVCN

low float

Neovasc Regains Compliance with Nasdaq Minimum Bid Price Rule

via NewMediaWire – Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN) announced today that it has received written notification from the Nasdaq Stock Market LLC (the “Nasdaq”) informing the Company that it has regained

RHEA-AI

neutral

05/12/22 4:05 PM

Nasdaq : NVCN

earningslow float

Neovasc Announces First Quarter Financial Results and Provides Corporate Update

Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today reported financial results for the quarter ended March 31, 2022. Recent Highlights · Achieved Q1 revenue of approximately $611,000, an

RHEA-AI

neutral

04/29/22 9:05 AM

Nasdaq : NVCN

conferencesearningslow float

Neovasc to Report First Quarter Financial Results on May 12, 2022

Neovasc Inc. ( NASDAQ , TSX : NVCN), will report financial results for the quarter ended March 31, 2022 on Thursday, May 12, 2022. Neovasc’s President and Chief Executive Officer Fred Colen, and Chris Clark,

RHEA-AI

neutral

04/28/22 9:05 AM

Nasdaq : NVCN

low float

Neovasc Comments on European Heart Journal Publication

Neovasc, Inc. ("Neovasc" or the "Company") ( NASDAQ, TSX : NVCN) today announced that the European Heart Journal has

RHEA-AI

neutral

04/27/22 4:05 PM

Nasdaq : NVCN

low float

Neovasc Announces Effective Date of Share Consolidation

Neovasc Inc. (" Neovasc" or the " Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive devices for the treatment of refractory angina, and in the development of minimally invasive transcatheter

RHEA-AI

neutral

1 2 3 4 5 6 7 8 Next

NVCN Data

IndustrySurgical and Medical Instrument Manufacturing
Websitewww.neovasc.com
CeoFred Colen
Security nameNeovasc Inc
Issue typecs
SectorManufacturing
Sic code3841
Employees71
Tags
- Health Technology
- Medical Specialties
- Manufacturing
- Surgical and Medical Instrument Manufacturing
AddressRichmond
Address25138-13562 Maycrest Way
StateBritish Columbia
CityRichmond
ZipV6V 2J7
CountryCanada
Phone16042704344

About Neovasc Inc

Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include Reducer, for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and Tiara, for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada, Israel and Europe.